Autonomix (AMIX) Medical announced the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,279,889 B2 titled, “Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification.” The newly issued ‘899 patent relates to but is not limited to advanced systems and methods for locating, monitoring and mapping electrophysiological signals before, during and following a neuromodulation or denervation procedures. Furthermore, the patent explicitly contemplates tools to access small vessels and navigation to the target area to treat cancerous tumors and the pain associated with cancerous tumors. The technology is designed to treat conditions influenced by sympathetic nerve activity, including renal denervation for hypertension, chronic pain syndromes, cardiac modulation and metabolic and neurological disorders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMIX:
- Autonomix granted approval to expand PoC human clinical trial
- Autonomix granted key U.S. patent for catheter-based platform technology
- Autonomix CEO outlines follow-on expansion study expected to begin in Q2
- Autonomix releases testimonial of patient in trial of pancreatic cancer pain
- Autonomix provides update on initial phase on delivering transvascular energy